ProQR Therapeutics (PRQR) to Release Earnings on Thursday

ProQR Therapeutics (NASDAQ:PRQR) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.1303) per share and revenue of $4.5610 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 12:30 PM ET.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). The company had revenue of $2.35 million during the quarter, compared to the consensus estimate of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. On average, analysts expect ProQR Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ProQR Therapeutics Trading Up 7.0%

Shares of PRQR stock opened at $1.83 on Wednesday. The company has a market cap of $192.81 million, a P/E ratio of -3.66 and a beta of 0.07. The firm has a fifty day moving average price of $1.68 and a 200 day moving average price of $1.65. ProQR Therapeutics has a 12 month low of $1.33 and a 12 month high of $3.10.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PRQR. Chardan Capital lowered their price objective on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, June 26th. JonesTrading lowered their price target on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Wall Street Zen lowered shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Finally, Weiss Ratings downgraded shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, ProQR Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

Insider Activity

In other news, CEO Boer Daniel Anton De purchased 150,000 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were bought at an average price of $1.74 per share, with a total value of $261,000.00. Following the completion of the transaction, the chief executive officer directly owned 300,000 shares in the company, valued at approximately $522,000. This represents a 100.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bart Filius acquired 150,000 shares of ProQR Therapeutics stock in a transaction on Friday, July 17th. The stock was purchased at an average price of $1.72 per share, with a total value of $258,000.00. Following the purchase, the director owned 300,000 shares of the company’s stock, valued at $516,000. The trade was a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 600,000 shares of company stock valued at $988,500 over the last three months. Company insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds have recently modified their holdings of PRQR. Ikarian Capital LLC raised its position in ProQR Therapeutics by 67.2% in the 4th quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock valued at $3,014,000 after purchasing an additional 600,000 shares during the last quarter. Citadel Advisors LLC grew its position in ProQR Therapeutics by 73.2% during the 3rd quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 277,749 shares during the last quarter. Millennium Management LLC increased its stake in ProQR Therapeutics by 80.8% in the fourth quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock valued at $879,000 after purchasing an additional 194,369 shares during the period. Two Sigma Investments LP raised its holdings in shares of ProQR Therapeutics by 86.3% in the third quarter. Two Sigma Investments LP now owns 417,300 shares of the biopharmaceutical company’s stock valued at $889,000 after buying an additional 193,260 shares during the last quarter. Finally, Palo Alto Investors LP acquired a new stake in shares of ProQR Therapeutics during the third quarter worth about $402,000. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.